PS
MYGN icon

Principal Securities’s Myriad Genetics MYGN Stock Holding History

Principal Securities’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-49
Closed -$354 – 2716
2025
Q3 		$354 Buy
+49
New +$291 ﹤0.01% 3587
2024
Q1 		– Sell
-476
Closed -$9.11K – 3369
2023
Q4 		$9.11K Buy
+476
New +$8.23K ﹤0.01% 2293

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Principal Securities's MYGN Position: Q4 2025 in Review

Principal Securities sold out of Myriad Genetics (MYGN) in Q4 2025, closing a stake of 49 shares — an estimated $354 sold.

Principal Securities first reported a position in MYGN in Q4 2023 and held it in 2 quarters. The position peaked at $9.11K in Q4 2023. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2025.

  • Principal Securities reported no remaining Myriad Genetics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 49 Myriad Genetics shares in Q4 2025, an estimated $354.
  • Principal Securities first reported a position in Myriad Genetics in Q4 2023 and held it in 2 quarters.
  • Principal Securities's Myriad Genetics position peaked at $9.11K in Q4 2023.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.